Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 15;123(24):4914-4923.
doi: 10.1002/cncr.30934. Epub 2017 Sep 8.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials

Wendy B London  1 , Rochelle Bagatell  2 , Brenda J Weigel  3 , Elizabeth Fox  2 , Dongjing Guo  4 , Collin Van Ryn  5   6 , Arlene Naranjo  5   6 , Julie R Park  7   8
Affiliations
Review

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials

Wendy B London et al. Cancer. .

Abstract

Background: Early-phase trials in patients with recurrent neuroblastoma historically used an objective "response" of measureable disease (Response Evaluation Criteria In Solid Tumors [RECIST], without bone/bone marrow assessment) to select agents for further study. Historical cohorts may be small and potentially biased; to the authors' knowledge, disease recurrence studies from international registries are outdated. Using a large recent cohort of patients with recurrent/refractory neuroblastoma from Children's Oncology Group (COG) modern-era early-phase trials, the authors determined outcome and quantified parameters for designing future studies.

Methods: The first early-phase COG trial enrollment (sequential) of 383 distinct patients with recurrent/refractory neuroblastoma on 23 phase 1, 3 phase 1/2, and 9 phase 2 trials (August 2002 to January 2014) was analyzed for progression-free survival (PFS), overall survival (OS), and time to disease progression (TTP). Planned frontline therapy for patients with high-risk neuroblastoma included hematopoietic stem cell transplantation (approximately two-thirds of patients underwent ≥1 hematopoietic stem cell transplantation); 13.2% of patients received dinutuximab.

Results: From the time of the patient's first early-phase trial enrollment (383 patients), the 1-year and 4-year PFS rates ( ± standard error) were 21% ± 2% and 6% ± 1%, respectively, whereas the 1-year and 4-year OS rates were 57% ± 3% and 20% ± 2%, respectively. The median TTP was 58 days (interquartile range, 31-183 days [350 patients]); the median follow-up was 25.3 months (33 patients were found to be without disease recurrence/progression). The median time from diagnosis to first disease recurrence/progression was 18.7 months (range, 1.4-64.8 months) (176 patients). MYCN amplification and 11q loss of heterozygosity were prognostic of worse PFS and OS (P = .003 and P<.0001, respectively, and P = .02 and P = .03, respectively) after early-phase trial enrollment.

Conclusions: This recent COG cohort of patients with recurrent/refractory neuroblastoma is inclusive and representative. To the authors' knowledge, the current study is the first meta-analysis of PFS, TTP, and OS within the context of modern therapy. These results will inform the design of future phase 2 studies by providing a) historical context during the search for more effective agents; and, b) factors prognostic of PFS and OS after disease recurrence to stratify randomization. Cancer 2017;123:4914-23. © 2017 American Cancer Society.

Keywords: International Neuroblastoma Response Criteria (INRC); Response Evaluation Criteria In Solid Tumors (RECIST); endpoints; historical standard; phase 2 design; prognostic.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Statement

All authors (WL, RB, BW, EF, DG, CVR, AN, and JP) declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic portrayal of TTFR (time to first relapse/progression after diagnosis), TTP (time to progression after first enrollment on an early-phase trial), PFS time (if neuroblastoma relapse, progression, or death from neuroblastoma), and OS time (if death).
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
Figure 2
Figure 2
A. Progression-free and overall survival curves from modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma: n=383 patients (first early-phase trial enrollment). Survival time is calculated starting from the time of first enrollment onto the early-phase trial. B. Distribution of time from early-phase trial enrollment until relapse/progression (TTP) (the n=350 subset who relapsed/progressed out of the overall 383 patients) C–E. Overall survival curves for 383 patients on modern-era COG early phase trials for treatment of relapsed or refractory neuroblastoma. C. By Era: 8/2002–4/2009 versus 5/2009–2/2014, p=0.008; D. By MYCN status: amplified versus not amplified, p<0.0001; E. By 11q status: LOH versus no LOH, p=0.03. Overall survival time is calculated starting from the time of first enrollment onto the COG early-phase trial. F–G. Progression-free survival curves for 383 patients on modern-era COG early-phase trials for treatment of relapsed or refractory neuroblastoma. F. By MYCN status: amplified versus not amplified, p=0.003; G. By 11q status: LOH versus no LOH, p=0.02. Progression-free survival time is calculated starting from the time of first enrollment onto the COG early-phase trial.
See this image and copyright information in PMC

References

    1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369:2106–2120. - PubMed
    1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216. - PubMed
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J National Cancer Inst. 2000 Feb 2;92(3):205–16. - PubMed
    1. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. - PubMed
    1. Castel V, Garcia-Miguel P, Canete A, et al. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. Eur J Cancer. 1999 Apr;35(4):606–611. - PubMed

MeSH terms

Substances